Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) stock closed at 0.7376 per share at the end of the most recent trading day (a -7.02% change compared to the prior day closing price) with a volume of 4.19M shares and market capitalization of 96.09M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 171 people. Adamis Pharmaceuticals Corporation CEO is Dennis J. Carlo.

The one-year performance of Adamis Pharmaceuticals Corporation stock is 101.77%, while year-to-date (YTD) performance is 52.05%. ADMP stock has a five-year performance of -90.93%. Its 52-week range is between 0.3163 and 2.34, which gives ADMP stock a 52-week price range ratio of 19.75%

Adamis Pharmaceuticals Corporation currently has a PE ratio of -2.00, a price-to-book (PB) ratio of 4.86, a price-to-sale (PS) ratio of 14.47, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -68.89%, a ROC of -87.87% and a ROE of -98.11%. The company’s profit margin is -%, its EBITDA margin is -169.00%, and its revenue ttm is $8.23 Million , which makes it $0.06 revenue per share.

Of the last four earnings reports from Adamis Pharmaceuticals Corporation, there were 0 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.05 for the next earnings report. Adamis Pharmaceuticals Corporation’s next earnings report date is 17th May 2021.

The consensus rating of Wall Street analysts for Adamis Pharmaceuticals Corporation is Moderate Buy (2.33), with a target price of $1.25, which is +74.51% compared to the current price. The earnings rating for Adamis Pharmaceuticals Corporation stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Adamis Pharmaceuticals Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Adamis Pharmaceuticals Corporation has a Sell technical analysis rating based on Technical Indicators (ADX : 23.79, ATR14 : 0.13, CCI20 : -193.28, Chaikin Money Flow : -0.25, MACD : -0.11, Money Flow Index : 30.43, ROC : -17.49, RSI : 36.99, STOCH (14,3) : 2.63, STOCH RSI : 0.29, UO : 41.23, Williams %R : -97.37), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Adamis Pharmaceuticals Corporation in the last 12-months were: David J. Marguglio (Option Excercise at a value of $0), David J. Marguglio (Sold 116 498 shares of value $73 423 ), Dennis J. Carlo (Option Excercise at a value of $0), Dennis J. Carlo (Sold 31 507 shares of value $19 436 ), Karen K. Daniels (Sold 15 668 shares of value $9 675 ), Robert O. Hopkins (Option Excercise at a value of $0), Robert O. Hopkins (Sold 76 179 shares of value $43 260 ), Ronald B. Moss (Option Excercise at a value of $0), Ronald B. Moss (Sold 25 017 shares of value $15 445 )